HomeMarket NewsSmall CapsKorro Bio Emerges Strong from Recent H.C. Wainwright Endorsement

Korro Bio Emerges Strong from Recent H.C. Wainwright Endorsement

Actionable Trade Ideas

always free


H.C. Wainwright initiated coverage onΒ Korro Bio IncΒ KRRO, a biotech company aimed at editing ribonucleic acid (RNA) for treating diseases.

Recently, Korro Bio merged withΒ Frequency Therapeutics Inc.Β in an all-stockΒ deal, resulting in about $170 million in post-transaction cash to fund operations into 2026.

Analysts Mitchell S. Kapoor and Raghuram Selvaraju initiated a Buy rating and set a price targetΒ of $100 per share.

Korro’s core technology, Oligonucleotide Promoted Editing of RNA (OPERA), taps into native biology to make a targeted base edit in the RNA sequence, yielding desired protein translation and function.

Korro’s OPERA platform allows it to pursue a wide range of indications, initially focusing on six potential programs correcting mutations or creating protein variants.

Korro’s preclinical data was generated using a lipid nanoparticle, already used in the approved RNA interference (RNAi)-based therapeutic,Β Alnylam Pharmaceuticals Inc’sΒ ALNY Onpattro (patisiran), indicated for a rare disorder.

The company’s lead program is Oligo A for alpha-1 antitrypsin deficiency (AATD), a rare genetic disorder mainly affecting the lungs and liver, leading to lung conditions and liver disease.

Price Action:Β KRRO shares are up 27% at $62.26, reflecting Korro Bio’s strong performance.

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.